Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 Study of Intravenous Anidulafungin in ICU Adults With Candidemia and Invasive Candidiasis
2007-004854-97Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2008
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anidulafungin in candidemia and invasive candidiasis, sponsored by Pfizer. Primary endpoint: Global treatment response at End of Treatment (EOT). Started Jan 2008; status: completed.
02
Drugs
anidulafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on 2007-004854-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004854-97.